SCHEDULE: Sirenia Capital Management Discloses 3.1% Stake in Dianthus Therapeutics

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 3.1% of Dianthus Therapeutics, Inc. common stock, including shares issuable from options.

Summary

• Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, indicating their beneficial ownership of 1,696,751 shares of Dianthus Therapeutics, Inc. common stock.
• This holding represents approximately 3.1% of the company's outstanding common stock as of May 1, 2026.
• The reported shares include 510,400 shares of common stock issuable upon the exercise of call options.
• Sirenia Capital Management LP is a Delaware limited partnership, and Alex Silverstein is a United States citizen and the managing member of Sirenia Capital Management GP LLC.
• Both parties certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake by an investment management firm, with no immediate negative implications.

Positives

• The filing indicates an investment by a professional management firm, which can be seen as a vote of confidence in the company's potential.
• The inclusion of shares issuable from options suggests a forward-looking investment strategy by Sirenia Capital Management.

Negatives

• The filing does not contain any negative financial or operational information about Dianthus Therapeutics.

Risks

• The primary risk is the potential for future changes in ownership or investment strategy by Sirenia Capital Management, which could impact share price.
• As with any investment, there is the inherent risk associated with market fluctuations and the performance of Dianthus Therapeutics.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Dianthus Therapeutics. The outlook is based on the investment position of Sirenia Capital Management.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing places Dianthus Therapeutics within the scope of active institutional investment, a trend seen across the biotechnology sector where strategic stakes can precede further corporate actions or influence.

Comparison to Industry Standards

• The 3.1% stake is a notable but not controlling position, typical for an initial or ongoing investment by an asset manager in the biotechnology sector.
• Many biotechnology companies experience similar levels of institutional ownership, with stakes often ranging from below 1% to over 10% for significant investors.
• The inclusion of exercisable options aligns with common investment strategies in the sector, aiming to capitalize on potential stock price appreciation.

Stakeholder Impact

• Shareholders: May view the investment by Sirenia Capital Management as a positive signal, potentially increasing interest and liquidity in the stock.
• Management: May need to engage with Sirenia Capital Management regarding their investment strategy and the company's performance.
• Potential Investors: This filing provides information about significant ownership, which can influence investment decisions.

Next Steps

• Continued monitoring of Sirenia Capital Management's investment activity in Dianthus Therapeutics.
• Observation of any future filings or disclosures by Sirenia Capital Management or Dianthus Therapeutics.

Key Dates

Keywords

Dianthus Therapeutics, Sirenia Capital Management, Schedule 13G, Beneficial Ownership, Investment Management, Call Options, Common Stock, SEC Filing